Invex Therapeutics Ltd

NEW
ASX:IXC (Australia)   Ordinary Shares
A$ 0.10 (0%) Jul 14
At Loss
P/B:
1.72
Market Cap:
A$ 7.89M ($ 5.50M)
Enterprise V:
A$ 3.30M ($ 2.30M)
Volume:
0
Avg Vol (2M):
54.09K
Trade In:

Business Description

Description
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.
Name Current Vs Industry Vs History
Cash-To-Debt
No Debt
Equity-to-Asset
0.96
Interest Coverage
No Debt
Piotroski F-Score
3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI
62.24
9-Day RSI
50.45
14-Day RSI
47.72
3-1 Month Momentum %
33.33
6-1 Month Momentum %
-7.69
12-1 Month Momentum %
33.33

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
26.84
Quick Ratio
26.84
Cash Ratio
26.11

Dividend & Buy Back

Name Current Vs Industry Vs History
Name Current Vs Industry Vs History
ROE %
-16.52
ROA %
-15.62
ROCE %
-26.13

Financials

ASX:IXC's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017

Invex Therapeutics Ltd Executives

Details

GF Valueâ„¢

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil A$)
EPS (TTM) (A$) -0.012
Beta 1.2546
3-Year Sharpe Ratio -0.03
3-Year Sortino Ratio -0.04
Volatility % 80.97
14-Day RSI 47.72
14-Day ATR (A$) 0.003009
20-Day SMA (A$) 0.10675
12-1 Month Momentum % 33.33
52-Week Range (A$) 0.075 - 0.18
Shares Outstanding (Mil) 75.15

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Invex Therapeutics Ltd Filings

Filing Date Document Date Form
No Filing Data

Invex Therapeutics Ltd Stock Events

Financials Calendars
Event Date Price (A$)
No Event Data

Invex Therapeutics Ltd Frequently Asked Questions

What is Invex Therapeutics Ltd(ASX:IXC)'s stock price today?
The current price of ASX:IXC is A$0.11. The 52 week high of ASX:IXC is A$0.18 and 52 week low is A$0.08.
When is next earnings date of Invex Therapeutics Ltd(ASX:IXC)?
The next earnings date of Invex Therapeutics Ltd(ASX:IXC) is .
Does Invex Therapeutics Ltd(ASX:IXC) pay dividends? If so, how much?
Invex Therapeutics Ltd(ASX:IXC) does not pay dividend.

Press Release

Subject Date
No Press Release

Articles on Invex Therapeutics Ltd

No articles.